home / stock / rlyb / rlyb news


RLYB News and Press, Rallybio Corporation From 09/19/22

Stock Information

Company Name: Rallybio Corporation
Stock Symbol: RLYB
Market: NASDAQ
Website: rallybio.com

Menu

RLYB RLYB Quote RLYB Short RLYB News RLYB Articles RLYB Message Board
Get RLYB Alerts

News, Short Squeeze, Breakout and More Instantly...

RLYB - Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2022 Update

Summary Halvorsen's 13F portfolio value decreased from $24.74B to $21.86B this quarter. The number of positions increased from 56 to 82. Viking Global added McKesson, American International Group, and Intuit while decreasing T-Mobile US, General Electric, and Brookfield Asset Mana...

RLYB - Rallybio to Present at the 2022 Wells Fargo Healthcare Conference

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a fireside chat at...

RLYB - Rallybio GAAP EPS of -$0.57 beats by $0.04

Rallybio press release ( NASDAQ: RLYB ): Q2 GAAP EPS of -$0.57 beats by $0.04 . As of June 30, 2022, cash, cash equivalents, and marketable securities were $147.4 million. For further details see: Rallybio GAAP EPS of -$0.57 beats by $0.04

RLYB - Rallybio Reports Second Quarter 2022 Financial Results

-- Emerging data from Phase 1b study of RLYB212 shows rapid and complete elimination of transfused HPA-1a positive platelets -- -- Phase 1 study of RLYB116 ongoing; initial single dose safety, PK, and PD data expected for the 30 mg dose in the 4Q 2022 -- Rallybio C...

RLYB - Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that it has appointed Wendy K. Chung, M.D., Ph.D., to its ...

RLYB - Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2022 Update

Halvorsen's 13F portfolio value decreased from $34.49B to $24.74B this quarter. The number of positions decreased from 107 to 56. Viking Global increased Amazon.com, Fortive, and International Flavors & Fragrances while dropping Humana, Coupa Software, and Twilio. The top thre...

RLYB - ADAP, SLDP and ZSAN among mid-day movers

Gainers: Turning Point Therapeutics (TPTX) +117%. Energy Focus (EFOI) +40%. Galecto (GLTO) +25%. Adaptimmune (ADAP) +22%. Amylyx Pharmaceuticals (AMLX) +22%. AudioEye (AEYE) +20%. Sprague Resources LP (SRLP) +20%. Global Cord Blood (CO) +18%. GreenBox (GBOX) +17%. Kopin (KOPN) +15%. Losers: N...

RLYB - Turning Point, Amylyx top healthcare gainers; Novavax, Rallybio lead losers' pack

Gainers: Turning Point Therapeutics (TPTX) +116%. Amylyx Pharmaceuticals (AMLX) +27%. Yumanity Therapeutics (YMTX) +11%. Amarin (AMRN) +9%. Galecto (GLTO) +8%. Losers: Novavax (NVAX) -13%. Rallybio (RLYB) -13%. Invitae (NVTA) -9%. Spruce Bioscience...

RLYB - Rallybio announces Jeffrey Fryer to retire from CFO position

Rallybio (NASDAQ:RLYB) has announced that Jeffrey Fryer, CPA, will retire from his position as CFO. Mr. Fryer will continue to serve as Rallybio’s CFO until a new CFO has been appointed and will retire from the Company following a transition period. Rallybio has initiated an external s...

RLYB - Rallybio Announces Retirement of Jeffrey Fryer, CPA, Chief Financial Officer

--Company initiates an external search for its next Chief Financial Officer-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare di...

Previous 10 Next 10